KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortization of GoodwillCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Evolent Health (EVH) Gains from Investment Securities (2016 - 2025)

Evolent Health (EVH) has 11 years of Gains from Investment Securities data on record, last reported at -$6.7 million in Q4 2025.

  • For Q4 2025, Gains from Investment Securities rose 35.99% year-over-year to -$6.7 million; the TTM value through Sep 2025 reached -$3.8 million, down 112.34%, while the annual FY2024 figure was $4.9 million, 67.9% down from the prior year.
  • Gains from Investment Securities reached -$6.7 million in Q4 2025 per EVH's latest filing, down from -$1.1 million in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $15.4 million in Q3 2024 and bottomed at -$17.7 million in Q4 2022.
  • Average Gains from Investment Securities over 5 years is -$496578.9, with a median of $140000.0 recorded in 2023.
  • Peak YoY movement for Gains from Investment Securities: crashed 5544.44% in 2022, then surged 10901.43% in 2024.
  • A 5-year view of Gains from Investment Securities shows it stood at $427000.0 in 2021, then plummeted by 4245.2% to -$17.7 million in 2022, then surged by 185.72% to $15.2 million in 2023, then crashed by 169.09% to -$10.5 million in 2024, then skyrocketed by 35.99% to -$6.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Gains from Investment Securities were -$6.7 million in Q4 2025, -$1.1 million in Q3 2025, and $3.2 million in Q2 2025.